Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche Delays CERA Oncology Filing Until 2009

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Roche is pushing back the timeline for filing its anti-anemia agent CERA, its continuous erythropoietin receptor activator, for the treatment of chemotherapy-associated anemia until 2009, the firm said Feb. 1

You may also be interested in...

Roche CERA submission

Roche's long-acting anemia agent CERA has an estimated mid-February 2007 user fee date following the firm's recent submission of a BLA, announced April 20. The firm is seeking an indication for anemia associated with chronic kidney disease. Roche highlighted the continuous erythropoietin receptor activator as having a distinct molecular interaction from that of other erythropoietin agents. The BLA is supported by six Phase III trials of patients treated every four weeks. Roche is continuing to point to CERA's dosing advantages. The firm also plans to submit a chemotherapy-induced anemia BLA in 2009 (1Pharmaceutical Approvals Monthly February 2006, p. 15)...

Roche Gearing For CERA Renal Anemia BLA In 2006

Roche is on-track to file a BLA for its CERA long-acting anti-anemia agent in 2006 after four Phase III trials met their primary endpoint of hemoglobin level maintenance, the firm said Dec. 16

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts